June 10th Review

DAN - sold for 31.39% $3010 gain, nice for one day trade.

SQNM - bought this morning dip at $4.55 and sold at $4.95 for 8.79% $880 profit, example of scalping trade. People always take profits after big runs, you need little more skills and fast determination for scalping trade. Quick $880 in 10 mins.

VRNM - chart break out in my radar this morning, got in at $1.76 for $1.81 break out and broke $1.81 easily and flying to .95(hod). sold at $1.90 for another quick and easy 18.68% $1846 profit.

Two new positions for tomorrow

DDSS - DD for DDSS, huge volume coming in today! over $2 today, $3 target at least

DDSS $1.77 FDA Approval Pending (Nasdaq)- Strong Buy

1)Partnerships for Trazadone in USA. Seeking a partner upon FDA Approval
Major partnership already with Tramadol with Purdue Pharma (Maker of Oxycontin)

2)Approval of Trazadone (DDS-04A) on July 18th via a 505 for formulation change
(PDUFA date of 7/18/09)
http://www.labopharm.com/default.aspx?id=214

3) Phase III study published in A peer-reviewed journal providing evidence-based information to practicing clinicians. The poster, entitled Once-Daily Trazodone in Major Depressive Disorder: Double-Blind, Placebo-Controlled Study, concludes Labopharm’s trazodone formulation is an effective and well-tolerated treatment for MDD patients, which improves quality of sleep.
http://www.psychiatrymmc.com/

4) 49th Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health to be held from June 29 to July 2, 2009- Will present positive Phase III Data they submitted for Trazadone approval to the FDA
http://www.nimh.nih.gov/research-funding/scientific-meetings/recurring-meetings/ncdeu/index.shtml

Poster of Phase III Study to Appear at Scientific Meeting in Florida
Labopharm will present a poster discussing the results of the Phase III clinical trial of its novel trazodone formulation at the 49th Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health to be held from June 29 to July 2, 2009. The poster, entitled Once-Daily Trazodone in Major Depressive Disorder: Double-Blind, Placebo-Controlled Study, concludes Labopharm’s trazodone formulation is an effective and well-tolerated treatment for MDD patients, which improves quality of sleep.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6337663

Co-sponsored by NIMH and the American Society of Clinical Psychopharmacology (ASCP), NCDEU is a scientific meeting that brings together academic researchers involved in clinical trials, research pharmacists, clinicians and clinical staff, and investigators with the pharmaceutical industry. The NCDEU program includes presentations and information from the National Institute of Mental Health, ASCP, and the Food and Drug Administration (FDA).

5) DDSS one of only 7 FDA approvals left on the year!
http://seekingalpha.com/article/136045-vanda-pharma-an-extreme-fda-trade-that-paid-9-more-to-go?source=yahoo

6)Approval of Trazadone in other countries

PINN - gas play, oil momo, volume alert, watching this since last year, all oil penny stocks are on fire. Target = $0.80 first and $1.60 next.

Stock of the Day

FTK - finally(?) moving, up 27% today, nice volume, oil price rising, looking so good everything, see you at $5.

GNVC / ANDS also closed strong today :)

--------------------------------------------------------------------------

Another sideway for the market today, four days straight. Oil prices strike new high for 2009, commodities and dollar price are rising. This is really confusing me, don't know which way to go.
But who cares? You always can find stocks you can profit with, right?

Good Luck

-Market Hunter-

Labels: acls, aft, ands, dan, DDSS, ftk, gnvc, mpg, nwd, PINN, sqnm, stock market review, VG, VRNM, 주식